A strain of Lactobacillus johnsonii and its post-biotics that simultaneously improves vaginal mucosal damage and inhibits vaginal inflammation

CN117821307BActive Publication Date: 2026-06-30JIANGNAN UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202311808622.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-25
Publication Date
2026-06-30
Estimated Expiration
2043-12-25

AI Technical Summary

Technical Problem

There is a lack of effective research in the current technology for improving vaginal mucosal damage and inhibiting vaginal inflammation, and the resources of probiotics for vaginal mucosal repair on the market are limited.

Method used

A strain of Lactobacillus johnsonii, CCFM1340, and its postbiotics were provided. Microbial preparations containing Lactobacillus johnsonii or its fermentation broth, lysis buffer, or lyophilized powder were prepared for use in the preparation of food, pharmaceuticals, or hygiene products. These preparations promoted vaginal epithelial cell migration and repair, reduced the content of soluble cadherin E, increased the expression of tight junction protein OCLN, reduced epithelial cell shedding, and decreased the secretion of myeloperoxidase and IL-1β.

Benefits of technology

It effectively improves vaginal mucosal damage, promotes epithelial cell repair, enhances vaginal mucosal barrier function, and inhibits vaginal inflammation. Specifically, it reduces the content of soluble cadherin E, increases OCLN expression, reduces epithelial cell shedding, reduces the secretion of MPO and IL-1β, and improves vaginal pathological features.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117821307B_ABST
    Figure CN117821307B_ABST
Patent Text Reader

Abstract

This invention discloses a strain of *Lactobacillus johnsonii* and its metabiotic that simultaneously improves vaginal mucosal damage and inhibits vaginal inflammation, belonging to the field of microbial technology. The *Lactobacillus johnsonii* strain of this invention was isolated from vaginal secretions of healthy women. It has the effects of improving vaginal mucosal damage and inhibiting vaginal inflammation, specifically manifested in: promoting the migration and repair of vaginal epithelial cells; reducing the content of soluble cadherin E in the vaginal mucosa of mice and increasing the expression of vaginal tight junction protein OCLN; reducing the shedding of vaginal mucosal epithelial cells; reducing the secretion of MPO and IL-1β in mice with vaginitis; and (6) improving the pathological characteristics of the vagina in mice. Therefore, this *Lactobacillus johnsonii* has great application potential in products that improve vaginal mucosal damage and inhibit vaginal inflammation.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • External biological preparation for feminine vagina prophylaxis and health-care as well as treatment of gynecological genital tract inflammation, and preparation method

    CN107456509A

  • Vaginal mucosa repair composition and preparation method thereof

    CN113633757A

  • Lactobacillus johnsonii (Ljohn-1) and applications thereof

    CN110777087A

  • Lactobacillus paracasei Lc19 and microbial preparation containing lactobacillus paracasei Lc19

    CN113201467A

  • Lactobacillus brevis and application thereof in resisting cervical cancer

    CN115806901A